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All Roads Lead to a Critical Serine Phosphorylation
The two reports from the Orr and Zoghbi groups involve
a series of experiments that span the gamut from proteo-
mic analysis to cell biology to disease modeling in miceNine inherited neurodegenerative disorders result from
and fruit flies. The initial observation that set the stagepolyglutamine expansions. Two recently published pa-
for subsequent studies was the detection of a phospho-pers on spinocerebellar ataxia type 1, together with
serine-containing peptide that mapped to amino acidstudies on spinobulbar muscular atrophy last year,
position 774–781 and the determination that phosphory-indicate that host protein context is the key arbiter
lation was occurring on serine 776 (Emamian et al.,of polyglutamine disease protein toxicity. This insight
2003). Interestingly, an antibody (PN1168) generated tomay represent the most important development in the
detect phospho-S776-ataxin-1 preferentially stainedfield since the recognition of nuclear inclusions or the
nuclear-localized ataxin-1 in the original B05 SCA1 mice.propensity of polyglutamine to aggregate. Indeed, an
The Orr group then set out to produce transgenic miceintimate and inextricable relationship may exist be-
that express polyglutamine-expanded ataxin-1 with antween polyglutamine neurotoxicity and the normal in-
alanine substituted for serine at position 776. Despiteteractions, domains, modifications, and functions of
expressing ataxin-1[82Q]-A776 at levels comparable tothe respective disease proteins.
those seen in the B05 SCA1 mice and, more importantly,
in Purkinje cell nuclei, the A776 mutant ataxin-1 trans-The spinocerebellar ataxias (SCAs) are a heterogeneous
genic mice showed minimal behavioral and histopatho-group of inherited neurodegenerative disorders that
logical abnormalities. The tendency of ataxin-1[82Q]-share the common feature of cerebellar degeneration.
A776 protein not to form aggregates was evidenced bySCA1 was the first SCA for which linkage was estab-
the lack of nuclear inclusions in the SCA1-82Q-A776lished and, as it turns out, was also the first SCA gene
mice and by the detection of insignificant quantities ofto be cloned (Orr et al., 1993). Patients with SCA1 harbor
ataxin-1[82Q]-A776 protein in insoluble fractions gener-CAG repeat expansions of 40 triplets in a novel gene
ated from transfected CHO cells.named “ataxin-1.” Thus, SCA1 became the third recog-
The corollary paper delves into the basis of ataxin-1nized “polyglutamine repeat disease,” one of nine disor-
phosphorylation and how it mediates pathogenesisders characterized by expansion of an unstable CAG
(Chen et al., 2003b). This study begins with a ratherrepeat in the coding region of unrelated genes. (In addi-
striking experiment that yields the presence of two im-
tion to SCA1, this group includes spinobulbar muscular
munoprecipitated protein bands in COS1 cells trans-
atrophy [SBMA], Huntington’s disease [HD], dentatoru- fected with polyglutamine-expanded ataxin-1 that are
bral-pallidoluysian atrophy [DRPLA], SCA 2, 3, 6, 7, and absent from COS1 cells transfected with ataxin-1[82Q]-
17.) The mapping, gene discovery, and numerous subse- A776. Peptide sequencing of these bands by mass spec-
quent studies aimed at understanding the pathogenesis trometry indicated that they are different isoforms of
of SCA1 are largely the product of a highly successful the 14-3-3 protein. After showing that coexpression of
collaboration between the laboratories of Harry Orr and 14-3-3 with ataxin-1 in HeLa cells actually stabilized
Huda Zoghbi. With their publication of two more intri- ataxin-1 protein with a serine at position 776, the Zoghbi
guing papers on SCA1 in recent issues of Neuron and group turned to a fruit fly model of SCA1 to evaluate
Cell (Emamian et al., 2003; Chen et al., 2003b), it is clear potential modification. Surprisingly, SCA1-14-3-3 dou-
that the Orr-Zoghbi collaboration remains both vital and ble-transgenic flies generated with a leaky UAS pro-
synergistic though now nearly two decades old. moter in the absence of a GAL4 driver displayed early
Once it was recognized that the polyglutamine dis- lethality, even though singly transgenic SCA1 flies lack-
eases share some key features, an approach in this field ing the GAL4 driver are relatively normal, consistent with
has been to study each disease individually, with the the stabilization of ataxin-1 protein by 14-3-3. In the final
expectation that an advance in our understanding of section of the paper, ataxin-1 is shown to be a substrate
any of them might be relevant to our understanding of of Akt kinase, and in vitro binding of ataxin-1 by 14-3-3
all of them. One example of the validity of this approach is demonstrated to be dependent upon Akt phosphory-
was the independent detection of neuronal intranuclear lation. These results suggest a model of SCA1 neurode-
inclusions (NIs) in SCA3 patients and an HD mouse. This generation in which Akt phosphorylation of polygluta-
mine-expanded ataxin-1 leads to its stabilization and
accumulation through a direct interaction with 14-3-3.*Correspondence: laspada@u.washington.edu
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Akt and 14-3-3: Two Proteins that Come with Well be a key step in the progression of SCA1, but not in
its initiation. Another enigmatic question relates to theKnown Reputations and Relationships
One of the most interesting aspects of the two SCA1 detection of ataxin-1 protein on Western blot in SCA1
transgenic mice. While lack of detection of the aggre-papers is the implication of the Akt kinase and 14-3-3
protein in the pathogenesis of a polyglutamine repeat gate-prone ataxin-1 S776 protein seems plausible, why
is it that the nonaggregating ataxin-1 A776 protein can-disease. Akt is a kinase that was discovered about 11
years ago, originally known as protein kinase B. Since its not be detected? Given the power of animal models for
testing hypotheses of pathogenesis, reasonable nextdiscovery, Akt has emerged as a key node in prosurvival
signaling pathways that operate within a wide range of steps might be to use these model systems to further
validate the presented schema. If Akt phosphorylation iscell types (Brazil et al., 2002). Akt is a well established
antiapoptotic signaling molecule, having been shown to required for disease pathogenesis, then crossing SCA1
transgenic mice with Akt knockout mice should amelio-phosphorylate the BH3-only protein Bad, the forkhead
transcription factor FKHRL1, caspase 9, and IB family rate cerebellar degeneration. It would also be nice to
generate SCA1 transgenic fruit flies that express ataxin-members to counteract their proapoptotic potential
(Datta et al., 1999). Akt function has been demonstrated 1[82Q]-A776 protein to confirm that this version of
ataxin-1 is innocuous in flies as it was in mice.to be relevant to the CNS, as IGF-1-dependent survival
of cerebellar granule cell neurons appears to be Akt The identification of an ataxin-1 serine residue as a
site of Akt phosphorylation and a specific 14-3-3 bindingkinase dependent (Linseman et al., 2002).
The 14-3-3 protein family consists of at least seven interaction appears on the surface to be an unexpected
development in the SCA field. However, at least twohighly homologous isoforms, which are highly con-
served evolutionarily, with the yeast protein BMH1 dis- other autosomal-dominant SCAs result from mutations
that likely affect phosphoregulation. SCA12 has beenplaying an impressive 70% amino acid similarity to the
epsilon isoform (Tzivion and Avruch, 2002). The 14-3-3 attributed to a nonpolyglutamine encoding CAG repeat
expansion in the promoter of PPP2R2B, the gene forproteins are among the most abundant proteins in the
central nervous system, estimated to account for the brain-specific regulatory subunit of a protein phos-
phatase (Holmes et al., 1999). While the mechanism ofroughly 1% of all soluble protein in the brain. While a
diverse range of functions have been suggested for the disease is unclear, it seems likely that a CAG repeat
expansion in the promoter would alter the expression14-3-3 protein family, one of 14-3-3s most important
roles is to serve as a regulatory factor that controls a level of this phosphatase subunit, perhaps affecting the
phosphorylation status of certain key proteins. Moreprotein’s function by binding to it and restricting it to a
certain subcellular compartment. Among the best recently, missense mutations in the regulatory domain
of the  subunit of protein kinase C were reported to beknown examples of this are the interactions of 14-3-3
with the Bad protein and FKHRL1, whereby 14-3-3 bind- the cause of a dominant nonepisodic cerebellar ataxia
(Chen et al., 2003a). Thus, it appears that one pathwaying to the phosphorylated versions of these proteins
restricts them to the cytosol. Interestingly, the function of cerebellar degeneration may involve altered protein
phosphorylation.of 14-3-3 is linked to Akt kinase in these cases, as Akt
phosphorylation of Bad and FKHRL1 is required for The Importance of Context
In addition to potentially uncovering an entirely novel14-3-3 binding.
Tantalizing Leads and Unanswered Questions ataxin-1 modification and interaction pathway, the Orr
and Zoghbi papers reinforce an important concept thatThe wealth of data presented in support of the Akt-
ataxin-1-14-3-3 model put forth by the Orr and Zoghbi is now emerging in the polyglutamine field: Disease pro-
tein context is key to elucidating the basis of degenera-groups is a testament to the fact that interdisciplinary
approaches combined with cross-species modeling tion. While ataxin-1 function is unknown, the fact re-
mains that the ataxin-1 protein contains an interactionstudies are a powerful strategy to tackle complicated
problems, such as that of neurodegeneration. Of course, domain that is subject to phosphoregulation, and this
aspect of ataxin-1 function is just as important as thecertain questions do remain. One issue is where (subcel-
lularly) is ataxin-1 phosphorylation occurring? Immuno- polyglutamine expansion for disease pathogenesis. The
implications of this observation are profound, as thisstaining of cerebellar sections from SCA1 mice with the
phosphoserine-specific antibody preferentially labels means that an understanding of the domains and func-
tions determined by disease protein context will be criti-ataxin-1 protein localized to the nucleus of Purkinje cells
(Emamian et al., 2003). Assuming that limited epitope cal for solving the mystery of why neurons degenerate
in the different polyglutamine disorders (see model inaccessibility in the cell bodies and dendrites is not the
explanation, then it would appear that ataxin-1 S776 Figure 1).
A striking example of the importance of host proteinphosphorylation is somehow linked to its transport into
the nucleus. As most models of Akt activation posit context is provided by the resolution of a decade-old
question regarding the gender specificity observed inthat Akt localizes to the plasma membrane upon PI3-K
interaction, how is it then that ataxin-1 phosphorylation SBMA. In contrast to the eight other polyglutamine dis-
eases, SBMA displays X-linked inheritance and affectsby Akt could be occurring at the nuclear boundary or
in association with nuclear transport factors? A related only males. This sex-limited pattern of inheritance has
been difficult to reconcile with the toxic gain-of-functionissue is the basis of Akt activation. If basal conditions
in the cerebellum do not permit significant activation of mechanism presumably shared by all polyglutamine dis-
eases. SBMA is caused by a polyglutamine expansionAkt to occur, then the activation of Akt would require
that a moderate degree of cellular stress or injury take within the androgen receptor (AR), a steroid receptor
superfamily member that acts as a ligand-inducible tran-place in the neurons of the cerebellum prior to Akt activa-
tion and subsequent ataxin-1 phosphorylation. If this is scription factor (La Spada et al., 1991). Until recently,
there were two competing hypotheses to explain genderthe case, then the Akt phosphorylation of ataxin-1 may
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originating from the interaction of the toxic polyglutam-
ine-containing protein with a limited number of primary
targets. As it is often assumed that the polyglutamine
diseases share a common mechanism, it should follow
that primary targets should be shared in the different
diseases. This view has been reinforced by a wealth of
evidence that expanded polyglutamine, the only feature
common to all these diseases, is by itself inherently
toxic. Yet, in many cases, the toxicity of expanded poly-
glutamine, either alone or in the context of truncated
host proteins, does not accurately recapitulate key as-
pects of disease. On the other hand, polyglutamine dis-
ease models utilizing full-length protein have been more
representative of the phenotype of interest and more
useful at dissecting out mechanisms. Such studies have
highlighted the importance of host protein context and
supported the view that expanded polyglutamine im-Figure 1. A Model for Polyglutamine Tract Neurotoxicity Based
poses toxic properties on the host protein.upon the Importance of Host Protein Context
One possible interpretation of this literature is thatOn the left, we see a hypothetical example of a disease protein
the toxic gain-of-function resulting from polyglutaminecontaining four different domains. The presence of domain 1 may
expansion involves an altered or amplified normal func-impart toxicity to the polyglutamine tract by augmenting the ability
of the expanded glutamine (Q) tract to undergo a conformational tion of the host protein and that the primary targets
change. Domain 2 could be a subcellular localization signal. Domain for each disease protein are their normal interacting
3 could be a cleavage site or an amino acid residue subject to partners. Such a model of polyglutamine neurotoxicity
phosphorylation. Finally, domain 4 may be an interaction domain would account for one of the most intriguing and enig-
that mediates protein binding. While this model emphasizes the role matic features of these diseases—cell-type specificity.
of these domains in imparting pathology to the disease protein,
Simply stated, the conundrum is this: while most of theit is also equally possible that the expanded polyglutamine tract
different polyglutamine disease proteins display over-eliminates a domain function(s) to cause disease (see #5). The obvi-
lapping patterns of expression throughout the CNS, onlyous implication of this model is that the normal functions and activi-
ties of the host protein are inextricably tied to their mechanism of certain populations of neurons degenerate in the differ-
pathogenesis. ent diseases. The problem of cell-type specificity is not
only relevant to the polyglutamine diseases; indeed, the
conundrum exists for other major neurodegenerative
specificity: substantially higher levels of circulating an- disorders, including Alzheimer’s disease, Parkinson’s
drogens in males versus random (or nonrandom) X inac- disease, and ALS. One of us has attempted to attack this
tivation in females. Two recent publications in Neuron problem by studying the basis of the cone-rod dystrophy
resolved this issue with surprising clarity. Takeyama et retinal degeneration seen in SCA7. After successfully
al. expressed full-length AR protein harboring a 52 gluta- recapitulating cone-rod dystrophy retinal degeneration
mine stretch in the Drosophila eye (Takeyama et al., in SCA7 transgenic mice, a possible mechanism was
2002). Remarkably, the flies exhibited no overt pheno- uncovered when evidence for a direct physical and func-
type unless they were exposed to ligand. This ligand- tionally significant interaction between ataxin-7 and the
induced degeneration was produced when flies were cone-rod homeobox protein CRX was found (La Spada
treated with either agonist or antagonist ligands, demon- et al., 2001). This work led our group to conclude that
strating that translocation to the nucleus is the key expansion of a polyglutamine tract in ataxin-7 trans-
event—not induction of gene expression. In an indepen- formed what was, perhaps, a functional interaction with
dent study, male transgenic mice expressing full-length CRX into a pathogenic encounter. Thus, the basis of
AR protein harboring a 97 glutamine stretch showed one aspect of cell-type specificity in SCA7 might stem
progressive muscular weakness and atrophy, while fe- from the fact that ataxin-7 normally interacts with CRX.
male mice showed an insignificant phenotype (Katsuno Subcellular Localization: Uniquely Important,
et al., 2002). Castration of male transgenic mice at pu- but Not Unifying…
berty prevented degeneration, while administration of Soon after the recognition of the polyglutamine diseases
androgens to females yielded a pronounced neuromus- as a distinct set of disorders, the subcellular site of
cular phenotype. In each case, neuromuscular dysfunc- toxicity became a controversial issue. The debate has
tion correlated with the presence of the polyglutamine- traditionally been framed as a choice between the nu-
expanded AR in the nucleus. With impeccable timing, cleus and the cytoplasm, with the expectation that this
a report of the first known cases of two women homozy- determination would provide mechanistic insight. As we
gous for an AR CAG repeat expansion appeared in press now know, most (but not all!) polyglutamine disorders
two weeks later (Schmidt et al., 2002). Aside from mild are characterized pathologically by an intranuclear ac-
cramping, these women exhibited no significant neuro- cumulation of mutant protein in the neuronal regions
muscular disease or electrophysiological abnormality, undergoing degeneration. Several disease-causing pro-
ruling out the X inactivation-protection hypothesis. teins normally reside in the nucleus, but others that do
Thus, it is now clear that polyglutamine expansion in not (reside in the nucleus) appear to redistribute to the
the AR protein is not sufficient to produce SBMA. nucleus in disease. Moreover, nuclear localization is re-
Primary Target versus Contextual Modulation quired to induce neurodegeneration in disease models
The diverse cellular abnormalities observed in models of (Katsuno et al., 2002; Klement et al., 1998; Saudou et al.,
1998; Takeyama et al., 2002). These data have been usedpolyglutamine disease are presumed to reflect a cascade
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to press the argument that the nucleus is the site where ine tract itself, many groups have also devoted them-
selves to the development of cellular and organismalexpanded polyglutamine exerts its toxicity. Equally
compelling, however, is the apparent absence of nuclear models. Recent work on SCA1 and on SBMA now sug-
gests that an understanding of the domains, interac-accumulation of the mutant protein in SCA2 and SCA6
(Huynh et al., 2000; Zhuchenko et al., 1997). From the tions, posttranslational modifications, and functions of
the different disease proteins may be critical to uncov-viewpoint of the common polyglutamine toxicity model,
this divergence in subcellular localization of aggregates ering polyglutamine disease mechanisms. We believe
that such an approach will be instrumental in movingcomplicates efforts to generate a unifying model. How-
ever, if normal functions and normal interactions of the the polyglutamine disease field forward and ultimately
will culminate in the identification of target events andhost protein are the key determinants of toxicity, then
variation in the subcellular localization of aggregates is interactions that should be amenable to therapeutic in-
tervention.not problematic in the least. Indeed, the debate between
nucleus and cytoplasm may be too blunt and simplistic
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Closing Thoughts
Although the polyglutamine repeat disease field is barely
12 years old, progress in understanding the basis of
polyglutamine disease neurotoxicity has been rapid.
While much of the focus has been upon the polyglutam-
